European Society for Molecular Imaging Meeting 2016
The European Society for Molecular Imaging (ESMI) will have its annual meeting on March 8-10 in Utrecht, the Netherlands. This meeting focuses on Imaging Sciences from basics to translational aspects.
We invite you to the MILabs’ industrial session on Adaptive PET, SPECT, Optical and CT Imaging. Many exiting preclinical and clinical molecular imaging applications will be discussed:
In the spotlight: MILabs Adaptive Molecular Imaging Platform
Over the last decade, MILabs has been developing a platform using detector designs for task-based molecular imaging. This adaptive imaging approach assures that the resources built into the platform can easily adapt to the changing research demands of its customers. A fast growing base of preclinical users is already benefiting from the use of the Adaptive PET and SPECT systems. New capabilities such as sub-mm resolution Concurrent PET/SPECT of co-injected tracers are dramatically extending the application reach of nuclear imaging. In addition, this year, MILabs is adding innovative Adaptive CT and Optical Imaging designs, thus lifting the utility of its adaptive platform far beyond the capabilities of other preclinical imaging systems. Read more
Duke-NUS Medical School in Singapore to install MILabs Adaptive PET/SPECT/CT
The Laboratory for Translational and Molecular Imaging (LTMI) at the Duke-NUS Medical School in Singapore will install a MILabs VECTor4CT system located inside their specific pathogen free – SPF – barrier facility. A major thrust of LTMI is to develop in vivo molecular imaging agents to study cancer biology, inflammation, infection, and brain and immune function, with an Asian disease-centric focus. Current research projects are supported by funding from the Singapore National Research Foundation, Singapore National Medical Research Council, and a number of industrial partners. Read more
Nanomedicine development requires highly sensitive dynamic and longitudinal imaging systems
Growing interest in the medical application of nanotechnology by researchers worldwide is leading to the development of novel nanomedicines. Application of nanocarriers is particularly interesting in oncology, where the leaky vasculature of tumors and the impaired lymphatic drainage allow high drug accumulation for more effective therapies. Efficient nanocarrier research puts high demands on nuclear imaging systems. Both uptake kinetics as well as whole-body biodistribution must be studied and quantified. With MILabs’ molecular imaging platform, researchers are able to conduct very accurate quantitative SPECT and PET studies essential for this research.
The authors of this publication used MILabs’ SPECT/CT system to obtain fast, high-resolution images at low doses to study both the uptake kinetics and the whole-body biodistribution of 111In-radiolabeled Pluronic Nanocarriers.
SPECT/CT Imaging of Pluronic Nanocarriers with Varying Poly(ethylene oxide) Block Length and Aggregation State
Arranja et al., Molecular Pharmaceutics, 2016
This publication utilizes the MILabs’ imaging system to acquire quantitative in vivo total-body biodistribution of different 111In-rabiolabeld nanocarriers by:
Low dose injection of < 3.6 MBq
Fast 4D imaging for time-activity curves with 15 s frames